Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
MWN-AI** Summary
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a biotechnology company specializing in allogeneic CAR T (AlloCAR T) treatments, announced an important legal victory following arbitration between Servier and Cellectis regarding cemacabtagene ansegedleucel (cema-cel). The ruling confirmed Allogene’s comprehensive control over cema-cel in the U.S., all EU member states, and the UK, while also paving the way for potential acquisition of global commercialization rights in regions like Japan and China.
The arbitration tribunal dismissed Cellectis’s claims of Servier's breaches of development obligations and rejected financial demands tied to milestone payments, asserting that these payments are contingent upon the FDA’s acceptance of a Biologics License Application (BLA). The tribunal's partial termination of a license concerning a previous product (UCART19 V1, discontinued in favor of cema-cel) directs Cellectis to negotiate a new license with Allogene on substantially similar terms should Allogene choose to pursue it.
With these legal uncertainties resolved, Allogene is now positioned to advance its clinical programs, notably as it approaches a significant interim futility analysis in the pivotal Phase 2 ALPHA3 trial of cema-cel for first-line (1L) consolidation treatment in large B-cell lymphoma (LBCL). This analysis is expected in the first half of 2026, marking a critical moment for Allogene and its CAR T innovation efforts.
Allogene’s strategy focuses on delivering readily available cell therapies with its allogeneic product candidates, aiming to enhance patient access while achieving scale in manufacturing. With a management team experienced in cell therapy, Allogene continues to cultivate its pipeline and navigate the evolving landscape of cancer treatment, while balancing the inherent risks associated with clinical development and commercialization.
MWN-AI** Analysis
Allogene Therapeutics Inc. (Nasdaq: ALLO) recently reported a significant legal victory that reaffirms its control over cemacabtagene ansegedleucel (cema-cel), crucial for its future growth prospects. The arbitration ruling in favor of Servier against Cellectis validates Allogene’s development and commercialization rights throughout the U.S., EU, and UK, and paves the way for acquiring global rights, including potential expansions into Japan and China.
This favorable ruling is timely as Allogene prepares for a pivotal analysis in the first half of 2026 regarding the ALPHA3 trial, which is investigating cema-cel as a first-line consolidation therapy for large B-cell lymphoma (LBCL). The ability to move forward with advanced clinical trials under strengthened legal protections enhances Allogene's credibility and market appeal.
Investors should view this development favorably; the clear path for full commercialization rights strengthens Allogene's competitive position in the burgeoning CAR T-cell therapy market, which is expected to generate substantial revenue growth in the coming years. The cema-cel therapy, an "off-the-shelf" AlloCAR T product, targets critical needs within hematologic malignancies, suggesting a robust market potential.
However, market participants should remain cautious regarding the inherent risks outlined in Allogene's disclosures. Areas such as clinical trial uncertainties, regulatory approvals, and potential manufacturing challenges could influence timelines and commercial viability. Additionally, the financial performance remains a concern, as Allogene will need to secure additional funding to navigate the costly drug development landscape.
In summary, with the arbitration ruling enhancing Allogene's strategic position and an imminent trial analysis on the horizon, potential investors may consider this as an entry point; however, they should remain vigilant of the challenges that lie ahead.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- Arbitration Ruling Reaffirms Allogene’s Full Control of Cemacabtagene Ansegedleucel (Cema-Cel)
- Decision Reconfirms Allogene’s Expanded Sub-License Covering EU and UK Rights with Options for Japan and China, Clearing the Path for Allogene to Acquire Full Global Rights
- 1H 2026 Interim Futility Analysis from the Pivotal Phase 2 ALPHA3 Trial with Cema-Cel in First-Line (1L) Consolidation Large B-Cell Lymphoma (LBCL) Remains on Track
SOUTH SAN FRANCISCO, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today noted the favorable outcome for Servier in its arbitration with Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) as it relates to cemacabtagene ansegedleucel (cema-cel). This decisive win reconfirmed Allogene’s full development and commercial control of cema-cel in the United States, all EU Member States, and the United Kingdom, while clearing the path to obtain full global commercialization rights from Servier.
In particular, the tribunal:
- Rejected Cellectis’s allegations relating to alleged breaches by Servier of its development obligations;
- Rejected Cellectis’s financial claims, finding that milestone payments tied to the pivotal trial are not due until U.S. Food and Drug Administration acceptance of a Biologics License Application (BLA); and
- Ordered only a partial termination of the license strictly limited to the UCART19 V1 product (formerly known as ALLO-501, which was discontinued in 2021 in favor of ALLO-501A/cema-cel) and directed Cellectis to negotiate in good faith a direct license to Allogene on terms substantially similar to the existing agreement, if Allogene elects to pursue it.
With this legal matter resolved, Allogene enters 2026 with improved fundamentals. The company is approaching one of the most meaningful catalyst periods in the allogeneic CAR T field, including a 1H 2026 interim futility analysis comparing MRD conversion with cema-cel following standard fludarabine/cyclophosphamide lymphodepletion versus observation in first line patients with large B-cell lymphoma (LBCL).
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow Allogene Therapeutics on X and LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. This press release may, in some cases, use terms such as “expect,” “project,” “plan,” “scheduled,” “on track,” “aim,” “will,” “may,” “could,” “guidance,” “estimate,” “can,” and “potential,” and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things: the timing for Allogene’s interim futility analysis from the pivotal phase 2 ALPHA3 trial in cema-cel; whether Allogene is approaching one of the most meaningful catalyst periods in the allogeneic CAR T field; and the potential for Allogene to obtain full global commercialization rights from Servier for cema-cel. Various factors may cause material differences between Allogene’s expectations and actual results, including risks and uncertainties related to: clinical development risks, including our novel allogeneic CAR T approach and the unproven first-line consolidation setting in LBCL, the possibility that early or Phase 1 data may not predict later outcomes, trial delays or enrollment challenges, and adverse events (including those previously observed in certain ALPHA3 arms); contractual and counterparty risks; regulatory risks, including potential FDA or foreign authority disagreement with plans or interpretations, requests for additional data or trials, and possible requirements related to MRD assays; manufacturing and CMC risks, including challenges in consistent, scalable manufacturing and technology implementation that could affect timelines, outcomes, or availability; reliance on third parties, including licensors and collaborators (e.g., Cellectis, Servier, and Foresight Diagnostics); and financial risks relating to continued operating losses, the need for additional financing, and the possibility of not meeting financial guidance. These and other risks are discussed in greater detail in Allogene’s filings with the Securities and Exchange Commission (SEC), including, without limitation, under the “Risk Factors” heading in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the SEC on November 6, 2025. Any forward-looking statements made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update forward-looking statements, whether as a result of new information, future events, or otherwise, after the date of this press release.
Allogene’s investigational AlloCAR T oncology products utilize Cellectis technologies. Cemacabtagene ansegedleucel (cema-cel) was developed based on an exclusive license granted by Cellectis to Servier. Servier has granted Allogene exclusive rights to cema-cel in the U.S., all EU Member States and the United Kingdom.
Allogene Media/Investor Contact:
Christine Cassiano
EVP, Chief Corporate Affairs & Brand Strategy Officer
Christine.Cassiano@allogene.com
FAQ**
How does the arbitration ruling impact Allogene Therapeutics Inc. ALLO’s strategy for global commercialization of cemacabtagene ansegedleucel (cema-cel) in major markets like Japan and China?
What are the implications of the 1H 20interim futility analysis for Allogene Therapeutics Inc. ALLO in terms of investor confidence and pipeline development?
With the arbitration case resolved, what are the next steps for Allogene Therapeutics Inc. ALLO in negotiating the terms for acquiring full global rights from Servier?
What potential risks and uncertainties should investors consider regarding Allogene Therapeutics Inc. ALLO's plans following the arbitration outcome and upcoming clinical milestones for cema-cel?
**MWN-AI FAQ is based on asking OpenAI questions about Allogene Therapeutics Inc. (NASDAQ: ALLO).
NASDAQ: ALLO
ALLO Trading
-7.15% G/L:
$2.4699 Last:
2,018,095 Volume:
$2.56 Open:
